Winslow Garrett, General Counsel of Galecto, Inc. ($GLTO), made two open market sales of company shares over the past year, totaling about $6,333. His most recent sale occurred on January 2, 2026. These transactions rank him 11,365th among 11,678 insiders in our database by sale value, well below the average of $8.6 million across 6.4 transactions per insider. He reported no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 23, 2026 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | A | Stock Option (right to buy) | 250000 | $0.00 | 250,000.0000 | 1,327,212 | 9999.99% | 18.84% |
| Jan. 2, 2026 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | M | Common Stock | 680 | $0.00 | 2,109.0000 | 1,327,212 | 47.59% | 0.05% |
| Jan. 2, 2026 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | S | Common Stock | 255 | $21.38 | 1,854.0000 | 1,327,212 | 12.09% | 0.02% |
| Jan. 2, 2026 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | M | Restricted Stock Units | 680 | $0.00 | 1,320.0000 | 1,327,212 | 34.00% | 0.05% |
| July 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | M | Common Stock | 680 | $0.00 | 1,689.0000 | 1,322,359 | 67.39% | 0.05% |
| July 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | S | Common Stock | 260 | $3.39 | 1,429.0000 | 1,322,359 | 15.39% | 0.02% |
| July 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | M | Restricted Stock Units | 680 | $0.00 | 2,000.0000 | 1,322,359 | 25.37% | 0.05% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | M | Restricted Stock Units | 1320 | $0.00 | 2,680.0000 | 0 | 33.00% | 0.00% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | M | Common Stock | 1320 | $0.00 | 1,480.0000 | 0 | 825.00% | 0.00% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | S | Common Stock | 471 | $5.60 | 1,009.0000 | 0 | 31.82% | 0.00% |
| Jan. 3, 2025 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | A | Stock Option (right to buy) | 6000 | $0.00 | 6,000.0000 | 0 | 9999.99% | 0.00% |
| Oct. 9, 2024 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | A | Stock Option (right to buy) | 15600 | $0.00 | 15,600.0000 | 0 | 9999.99% | 0.00% |
| Jan. 3, 2024 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | A | Restricted Stock Units | 100000 | $0.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 4, 2023 | Damora Therapeutics, Inc. | $DMRA | Winslow Garrett | General Counsel | A | Stock Option (right to buy) | 80000 | $0.00 | 80,000.0000 | 0 | 9999.99% | 0.00% |